RT Journal Article
SR Electronic
T1 Influence of treatment on leptin levels in patients with obstructive sleep apnoea
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 601
OP 604
DO 10.1183/09031936.04.00067804
VO 23
IS 4
A1 B.M. Sanner
A1 P. Kollhosser
A1 N. Buechner
A1 W. Zidek
A1 M. Tepel
YR 2004
UL http://erj.ersjournals.com/content/23/4/601.abstract
AB Obstructive sleep apnoea syndrome (OSAS) is a common disorder in obesity. Leptin, an adipocyte-derived signalling factor, plays an important role in metabolic control. There is growing evidence that leptin regulation is altered in OSAS. Therefore, the aim of this study was to test the hypothesis that effective treatment will influence leptin levels in OSAS patients. Serum leptin levels were determined in 86 consecutive patients (aged 57.5±11.0 yrs) with polysomnographically verified OSAS. In addition, leptin levels were reassessed and treatment efficacy was evaluated by polysomnography after 6 months of therapy. Patients were treated with continuous or bilevel positive airway pressure, a mandibular advancement device or conservatively, depending on the clinical symptoms. Mean serum leptin levels did not change with treatment in the whole study group (7.3±5.0 versus 7.5±4.8 ng·mL−1), however, leptin levels decreased in effectively treated patients (8.5±5.0 versus 7.4±5.1 ng·mL−1) while they increased in ineffectively treated patients (5.0±4.0 versus 7.7±4.1 ng·mL−1). Furthermore, not only was there a significant and independent correlation between the change in leptin levels with treatment and the change in body mass index, but also with the change in apnoea/hypopnoea index. Effective treatment of sleep-disordered breathing may have significant effects on leptin levels in obstructive sleep apnoea syndrome patients. Changes in leptin levels are related to changes in apnoea/hypopnoea index in obstructive sleep apnoea syndrome patients.